구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Lapine T-Lymphocyte Immune Globulin (Lapine T-Lymphocyte Immune Globulin) M.D. Anderson Cancer Center·Acute Lymphoblastic Leukemia 32 trials |
|---|---|
Overview Program | Lapine T-Lymphocyte Immune Globulin |
Overview Company | M.D. Anderson Cancer Center |
Overview Modality | CGT |
Overview Target | Acute Lymphoblastic Leukemia |
Overview Indication | Beta Thalassemia Major; Sickle Beta 0 Thalassemia |
Overview Phase | PHASE_3 |
Overview Status | RECRUITING |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
MoA Biomarker | biomarkers of immunotherapy response in new-onset type 1 diabetes |
PK/PD Species | Rabbit, Human |
PK/PD Animal (cat.) | Human |
PK/PD Experiment | Pharmacokinetic |
Toxicology Species | Rabbit, Human |
Toxicology Animal (cat.) | Human |
Toxicology Major finding | thrombocytopenia, graft loss, and acute rejection |
Toxicology CRS | Reported |
Clinical Safety signal | thrombocytopenia, graft loss, and acute rejection |
Clinical Reported PFS | 24 |
Clinical Reported OS | 25 |
Clinical Result source | ClinicalTrials.gov NCT00572897 |
Clinical Program phase | PHASE_3 |
Clinical Trial ref | NCT00572897 |
Preclinical Animal (cat.) | Human, NHP, In vitro |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Lapine T-Lymphocyte Immune Globulin (Lapine T-Lymphocyte Immune Globulin) M.D. Anderson Cancer Center·Acute Lymphoblastic Leukemia 32 trials |
|---|---|
Overview Program | Lapine T-Lymphocyte Immune Globulin |
Overview Company | M.D. Anderson Cancer Center |
Overview Modality | CGT |
Overview Target | Acute Lymphoblastic Leukemia |
Overview Indication | Beta Thalassemia Major; Sickle Beta 0 Thalassemia |
Overview Phase | PHASE_3 |
Overview Status | RECRUITING |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
MoA Biomarker | biomarkers of immunotherapy response in new-onset type 1 diabetes |
PK/PD Species | Rabbit, Human |
PK/PD Animal (cat.) | Human |
PK/PD Experiment | Pharmacokinetic |
Toxicology Species | Rabbit, Human |
Toxicology Animal (cat.) | Human |
Toxicology Major finding | thrombocytopenia, graft loss, and acute rejection |
Toxicology CRS | Reported |
Clinical Safety signal | thrombocytopenia, graft loss, and acute rejection |
Clinical Reported PFS | 24 |
Clinical Reported OS | 25 |
Clinical Result source | ClinicalTrials.gov NCT00572897 |
Clinical Program phase | PHASE_3 |
Clinical Trial ref | NCT00572897 |
Preclinical Animal (cat.) | Human, NHP, In vitro |
추천 비교
추천 비교